The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 40.00
Ask: 43.00
Change: 0.50 (1.22%)
Spread: 3.00 (7.50%)
Open: 41.50
High: 41.50
Low: 41.50
Prev. Close: 41.00
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AquaInSilico wins grant to commercialise software

14 Jul 2020 07:00

RNS Number : 8772S
Frontier IP Group plc
14 July 2020
 

RNS Reach 

AIM: FIPP 

14 July 2020  

 

 

Frontier IP Group Plc 

("Frontier IP" or the "Group") 

 

Portfolio news - new portfolio company AquaInSilico wins grant to commercialise wastewater treatment software

 

Frontier IP, a specialist in commercialising intellectual property, today announces portfolio company AquaInSilico Lda (the "Company") has won a €60,000 EIT RawMaterials grant to further develop its software tools to optimise wastewater treatment.

 

The grant, from the European Union's European Institute of Innovation and Technology, will allow AquaInSilico to build on its collaboration with a leading European environmental, water and waste management group to commercialise its software tools to remove phosphorus from wastewater in a more environmentally friendly and effective way than existing methods. The recovered phosphorus can then be sold for use in fertilisers.

 

Several European countries, including Germany, Switzerland, Sweden and Austria, are introducing stricter regulations that require large treatment plants to recover at least 50 per cent of the phosphorus for use as a biofertilizer.

 

This is causing utilities problems because current methods use expensive and environmentally unfriendly chemicals to bind the phosphorus or biological processes that, although cheaper and more sustainable, do not work properly more than 45 per cent of the time.

 

AquaInSilico's software uses a mathematically-modelled biological approach to improve phosphorus removal, based on understanding and controlling the operating variables that result from biological and chemical processes. As a result, the process reduces the use of chemicals and energy, and the risk of environmental harm from phosphorus leaching into waterways from wastewater sludge.

 

The Company is a spin out from Portugal's NOVA University, NOVA School of Science and Technology ("FCT NOVA") and is the fourth spin out resulting from Frontier IP's growing presence in the country.

 

As the sophisticated algorithms the Company is developing are based on deep knowledge of biological and chemical processes and are able to understand and predict how they unfold in different conditions, they can detect possible problems, often before they can be diagnosed by humans.

 

As a result, the technology has broad applicability, with the potential to allow companies, such as oil groups, brewers, pulp, paper, steel makers, food processing and waste recovery businesses and municipal wastewater treatment plants, to tune and adapt their treatment systems more effectively. It is expected to save them up to 25 per cent of their operating costs.

 

It also supports the improved recovery of other valuable and recyclable products in addition to phosphorus, such as ammonia, biogas, and fine chemicals that can be used in biofertilisers, bioplastics and biofuels. The Company believes this could result in new sustainable technologies in future.

 

AquaInSilico was established to develop and commercialise the research of Dr Jorge Santos, Dr Mariana Matos and Professor Maria Ascensão Reis of FCT NOVA. This team had developed several research projects in environmental and industrial bioengineering in collaboration with several worldwide industry players. 

 

AquaInSilico co-founder, Dr. Jorge Santos, said" We are very happy for this EIT RawMaterials Booster grant, which offers us the opportunity to speed up our technology readiness level and reach the market with a solution that recovers critical raw materials from waste to new bio-based products." 

 

Frontier IP Chief Executive Officer, Neil Crabb, said: "AquaInSilico has been making good progress in collaboration with its industry partners, progress reflected and validated by the award of this grant to commercialise the technology." 

 

 

This activity has received funding from the European Institute of Innovation and Technology (EIT). This body of the European Union receives support from the European Union's Horizon 2020 research and innovation programme.

 

 

 

 

 

 

ENQUIRIES 

 

 

 

Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive

 

Andrew Johnson, Communications & Investor Relations

 

Company website: www.frontierip.co.uk

neil@frontierip.co.uk

 

M: 07464 546 025

 

Allenby Capital Limited (Nominated Adviser)

 

T: 0203 328 5656

Nick Athanas / Nicholas Chambers

 

 

 

 

 

 

ABOUT FRONTIER IP 

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs. 

 

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development. 

 

ABOUT EIT RAWMATERIALS

 

 EIT RawMaterials, initiated and funded by the EIT (European Institute of Innovation and Technology), a body of the European Union, is the largest consortium in the raw materials sector worldwide. Its vision is to develop raw materials into a major strength for Europe. Its mission is to enable sustainable competitiveness of the European minerals, metals and materials sector along the value chain by driving innovation, education and entrepreneurship.

EIT RawMaterials unites more than 120 core and associate partners and 180+ project partners from leading industry, universities and research institutions from more than 20 EU countries. Partners of EIT RawMaterials are active across the entire raw materials value chain; from exploration, mining and mineral processing to substitution, recycling and circular economy. They collaborate on finding new, innovative solutions to secure the supplies and improve the raw materials sector in Europe.

 

About RNS Reach announcements 

 

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABRGDRRDBDGGX
Date   Source Headline
7th May 202410:15 amRNSTVG to collaborate with The Pirbright Institute
2nd May 20247:00 amRNSFrontier IP announces stake in DiaGen
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.